Evaluating antiarrhythmic drugs for managing infants with supraventricular tachycardia; a review

Area of Science:

• Pediatric Cardiology
• Clinical Electrophysiology
• Pharmacology

Background:

• Supraventricular tachycardia (SVT) is the most common heart rhythm disorder in infants.
• Infantile SVT often presents within the first two months of life, affecting infants with and without congenital heart disease.
• Current treatment strategies for infant SVT lack a definitive consensus on the most effective antiarrhythmic medication.

Purpose of the Study:

• To systematically review updated antiarrhythmic drug therapies for managing supraventricular tachycardia (SVT) in infants under one year of age.
• To address the global challenge of varying management approaches and the absence of an optimal treatment strategy for infantile SVT.
• To provide an updated evidence-based overview for clinicians treating this prevalent pediatric arrhythmia.

Main Methods:

• Systematic literature search for recent studies on antiarrhythmic drugs used in infants with SVT.
• Analysis of drug efficacy, safety, and specific considerations for the pediatric population.
• Synthesis of findings to identify trends and potential optimal therapeutic options.

Main Results:

• Identification of several antiarrhythmic agents utilized in infant SVT management.
• Variability in reported efficacy and side effect profiles across different medications.
• Emerging data on novel therapeutic approaches and drug combinations.

Conclusions:

• The optimal antiarrhythmic drug for infant SVT remains undetermined, necessitating further research.
• Evidence-based guidelines are needed to standardize treatment protocols for infantile supraventricular tachycardia.
• Continued evaluation of updated antiarrhythmic therapies is crucial for improving patient outcomes.